Overview
The purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery.
The main questions it aims to answer are:
- 7-year ipsilateral breast tumor recurrence
- 7-year disease-free survival
- 7-year locoregional recurrence
- 7-year overall survival
- Adverse events of radiation therapy
Participants will be assessed by multi-dimensional methods after radiation therapy:
- Assessment for the disease status (disease-free or recurrence) including physical and radiologic examination
- Assessment for the adverse events according to CTCAE version 5.0
Eligibility
Inclusion Criteria:
- Female patients with age minimum 19
- Pathological confirmation of HER2+ invasive breast cancer
- Eastern Cooperative Oncology Group performance status 0-2
- Informed consent of the participant
Exclusion Criteria:
- Pathological confirmation of ductal carcinoma in situ of the breast
- Previous history of radiation therapy to ipsilateral breast